Literature DB >> 12895697

HIV-1 resistance to the gp41-dependent fusion inhibitor C-34.

Mercedes Armand-Ugón1, Arantxa Gutiérrez, Bonaventura Clotet, José A Esté.   

Abstract

The gp41 subunit of HIV-1 has been recently recognized as a target for antiviral therapy. C-34 is a peptide that mimics the heptad repeat 2 in the ectodomain of gp41. Here, we describe two HIV-1 strains selected after 5 and 17 passages in culture with increasing concentrations of C-34 (breakthrough concentration of 10 microg/ml). The HXB2-derived strain was more than 1000-fold resistant and contained a V38E mutation in the gp41 coding DNA sequence. The NL4-3-derived strain was more than 500-fold resistant and contained a L33S mutation in gp41. No cross-resistance to the RT inhibitor AZT, the HIV binding inhibitor dextran sulfate (DS), or the chemokine receptor antagonist ALX-40-4C was detected. These data indicate that HIV-1 can overcome C-34 inhibition through mutations at residues not involved in the formation of the hydrophobic cavity of gp41.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12895697     DOI: 10.1016/s0166-3542(03)00071-8

Source DB:  PubMed          Journal:  Antiviral Res        ISSN: 0166-3542            Impact factor:   5.970


  23 in total

1.  Mutations of Gln64 in the HIV-1 gp41 N-terminal heptad repeat render viruses resistant to peptide HIV fusion inhibitors targeting the gp41 pocket.

Authors:  Xiaowen Yu; Lu Lu; Lifeng Cai; Pei Tong; Suiyi Tan; Peng Zou; Fanxia Meng; Ying-Hua Chen; Shibo Jiang
Journal:  J Virol       Date:  2011-10-19       Impact factor: 5.103

2.  Structural basis of potent and broad HIV-1 fusion inhibitor CP32M.

Authors:  Xue Yao; Huihui Chong; Chao Zhang; Zonglin Qiu; Bo Qin; Ruiyun Han; Sandro Waltersperger; Meitian Wang; Yuxian He; Sheng Cui
Journal:  J Biol Chem       Date:  2012-06-07       Impact factor: 5.157

3.  ADS-J1 inhibits HIV-1 entry by interacting with gp120 and does not block fusion-active gp41 core formation.

Authors:  Emmanuel González-Ortega; Maria-Pau Mena; Marc Permanyer; Ester Ballana; Bonaventura Clotet; José A Esté
Journal:  Antimicrob Agents Chemother       Date:  2010-07-19       Impact factor: 5.191

4.  The cytoplasmic tail slows the folding of human immunodeficiency virus type 1 Env from a late prebundle configuration into the six-helix bundle.

Authors:  Levon G Abrahamyan; Samvel R Mkrtchyan; James Binley; Min Lu; Grigory B Melikyan; Fredric S Cohen
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

5.  Potent HIV fusion inhibitors against Enfuvirtide-resistant HIV-1 strains.

Authors:  Yuxian He; Jianwei Cheng; Hong Lu; Jingjing Li; Jie Hu; Zhi Qi; Zhonghua Liu; Shibo Jiang; Qiuyun Dai
Journal:  Proc Natl Acad Sci U S A       Date:  2008-10-13       Impact factor: 11.205

6.  A suite of modular fluorescence assays interrogate the human immunodeficiency virus glycoprotein-41 coiled coil and assist in determining binding mechanism of low molecular weight fusion inhibitors.

Authors:  Miriam Gochin
Journal:  Assay Drug Dev Technol       Date:  2012-08-16       Impact factor: 1.738

7.  Inhibition of coreceptor-independent cell-to-cell human immunodeficiency virus type 1 transmission by a CD4-immunoglobulin G2 fusion protein.

Authors:  Berta Bosch; Julià Blanco; Eduardo Pauls; Imma Clotet-Codina; Mercedes Armand-Ugón; Boyan Grigorov; Delphine Muriaux; Bonaventura Clotet; Jean-Luc Darlix; José A Esté
Journal:  Antimicrob Agents Chemother       Date:  2005-10       Impact factor: 5.191

8.  Design of peptide-based inhibitors for human immunodeficiency virus type 1 strains resistant to T-20.

Authors:  Kazuki Izumi; Eiichi Kodama; Kazuya Shimura; Yasuko Sakagami; Kentaro Watanabe; Saori Ito; Tsuyoshi Watabe; Yukihiro Terakawa; Hiroki Nishikawa; Stefan G Sarafianos; Kazuo Kitaura; Shinya Oishi; Nobutaka Fujii; Masao Matsuoka
Journal:  J Biol Chem       Date:  2008-12-10       Impact factor: 5.157

9.  Mechanism of resistance to S138A substituted enfuvirtide and its application to peptide design.

Authors:  Kazuki Izumi; Kumi Kawaji; Fusasko Miyamoto; Kazuki Shimane; Kazuya Shimura; Yasuko Sakagami; Toshio Hattori; Kentaro Watanabe; Shinya Oishi; Nobutaka Fujii; Masao Matsuoka; Mitsuo Kaku; Stefan G Sarafianos; Eiichi N Kodama
Journal:  Int J Biochem Cell Biol       Date:  2013-01-26       Impact factor: 5.085

10.  Asymmetric deactivation of HIV-1 gp41 following fusion inhibitor binding.

Authors:  Kristen M Kahle; H Kirby Steger; Michael J Root
Journal:  PLoS Pathog       Date:  2009-11-26       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.